Clinical trials: Adult Patients With Moderately to Severely Active Ulcerative Colitis, open to volunteers
- Condition Adult Patients With Moderately to Severely Active Ulcerative Colitis
- Status Open to volunteers
Ulcerative Colitis
Study to Assess Change in Disease Activity of Risankizumab Treatment in Adult Participants With Moderate to Severe Ulcerative Colitis
Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine).
- Trial name
- NCT06764706
- Where
- 57 sites in Germany
- Volunteers
- 200 people
- Sponsor
- AbbVie
Adult Patients With Moderately to Severely Active Ulcerative Colitis
A Phase 2 Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of HRS-7085 Tablets in Patients With Inflammatory Bowel Disease
This study is a randomized, double-blind, placebo-controlled Phase II clinical trial comprising screening period, treatment period, and follow-up period.
- Trial name
- NCT07229950
- Testing
- HRS-7085
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Moderately to Severely Active Ulcerative Colitis (UC)
Efficacy and Safety of IPG11406 in Moderately to Severely Active Ulcerative Colitis (Phase 2)
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and pharmacokinetics of IPG11406, an investigational oral drug, in adult patients with moderately to severely…
- Trial name
- NCT07535489
- Testing
- IPG11406
- Where
- China
- Volunteers
- 144 people
- Sponsor
- Nanjing Immunophage Biotech Co., Ltd
Inflammatory Bowel Diseases
Clinical Trial of TQH3906 Capsules for the Treatment of Adult Patients With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease
This phase will commence following dose escalation in the 24mg bid group during Phase I. Employing a 1:1:1 randomized, double-blind, placebo-controlled study design, it will evaluate the efficacy, safety, and…
- Trial name
- NCT06754891
- Testing
- 24mg bid TQH3906 capsule, 32mg TQH3906 capsule
- Where
- 30 sites in China
- Volunteers
- 135 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.